glp 1's The Latest on GLP-1s | Lexington Medical Center Blog GLP-1 Agonists: A Comprehensive Overview

how far findings apply to non-diabetic, normal weight older adults remains unknown

For patients pursuing serious, sustained weight management who meet clinical criteria

Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated

Individualization is Key: The ADA strongly advocates tailoring HbA1c goals based on: Duration of diabetes Risk of hypoglycemia Life expectancy Comorbidities (cardiovascular disease, CKD) Patient preference and treatment burden Beyond HbA1c: Modern diabetes care increasingly integrates Continuous Glucose Monitoring (CGM) metrics such as Time in Range (TIR) alongside HbA1c

Millions of Americans have turned to cheaper, compounded versions of Ozempic and Wegovy

The European Cardiovascular Health Plan Roadmap from the European Alliance was published earlier in 2025 and calls for comprehensive approaches to incorporate the recognition of obesity as a trigger for cardiovascular disease